Photo from archive.org
PD-L1 expression levels derived from >16,000 samples guided the selection of tumor types likely to benefit from pembrolizuamb monotherapy in clinical trials. Although not fail-proof, FDA approvals for most of… Click to show full abstract
PD-L1 expression levels derived from >16,000 samples guided the selection of tumor types likely to benefit from pembrolizuamb monotherapy in clinical trials. Although not fail-proof, FDA approvals for most of the prioritized indications speak to the power of RNA expression profiling and the value of large genomic datasets. See related article by Ayers et al., p. 1564
Keywords:
based rna;
treatment response;
predicting treatment;
expression;
response based;
rna expression
Journal Title: Clinical Cancer Research
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Clinical Cancer Research
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!